Harvey, Edward P.
Shin, Jung-Eun
Skiba, Meredith A.
Nemeth, Genevieve R.
Hurley, Joseph D. http://orcid.org/0000-0002-3903-318X
Wellner, Alon
Shaw, Ada Y.
Miranda, Victor G. http://orcid.org/0000-0001-8631-4622
Min, Joseph K.
Liu, Chang C. http://orcid.org/0000-0002-3290-2880
Marks, Debora S. http://orcid.org/0000-0001-9388-2281
Kruse, Andrew C. http://orcid.org/0000-0002-1467-1222
Funding for this research was provided by:
Helen Hay Whitney Foundation (N/A)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007226, T32GM132089)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Gordon and Betty Moore Foundation (N/A)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA260415, R01CA260415, R01CA260415)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (R21HD101596)
Article History
Received: 27 April 2022
Accepted: 22 November 2022
First Online: 7 December 2022
Competing interests
: C.C.L is a co-founder of K2 Biotechnologies Inc., which applies continuous evolution technologies to antibody engineering. D.S.M. is an advisor for Dyno Therapeutics, Octant, Jura Bio, Tectonic Therapeutic and Genentech, and is a co-founder of Seismic Therapeutic. A.C.K. is a co-founder and consultant for biotechnology companies Tectonic Therapeutic and Seismic Therapeutic, and for the Institute for Protein Innovation, a non-profit research institute. The remaining authors declare no competing interests.